Continuing Education Instructions and Disclosure Information:

Contact hours available until 4/30/2025.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty, reviewers, authors):

Editorial Board Disclosures:
Paula Dutka, MSN, RN, CNN, disclosed that she is a coordinator of clinical trials for the following spon¬sors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

Author(s) Disclosures:
Ellen D. Dillavou disclosed that she is a Consultant for WL Gore, 3M/KCI; a scientific advisor to BD and Boston Scientific; and the Dialysis Access Section Editor for UpToDate.

Commercial Support:
No commercial support declared.

This article was reviewed for contact hour value by Beth Ulrich, EdD, RN, FACHE, FAONL, FAAN, Nephrology Nursing Journal Editor-in-Chief, and Cynthia Calabrese, MSN, RN, NPD-BC, RN-BC, ANNA Director of Education Services.

Accreditation Statement:
The American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.

This NCPD article meets the Nephrology Nursing Certification Commission’s (NNCC’s) continuing nursing education requirements for certification and recertification.

ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this learning activity, readers will be able to discuss how a hemodialysis center assessment tool for early detection of dialysis access-associated steal syndrome (DASS) leads to less permanent injuries and tissue loss in patients on hemodialysis.

Ellen D. Dillavou MD, FACS

Appearances